257 related articles for article (PubMed ID: 25338077)
41. Genetic predisposition to papillary thyroid cancer.
Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D
Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463
[TBL] [Abstract][Full Text] [Related]
42. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
43. The familial counterparts of follicular cell--derived thyroid tumors.
Prazeres H; Torres J; Soares P; Sobrinho-Simões M
Int J Surg Pathol; 2010 Aug; 18(4):233-42. PubMed ID: 20444727
[TBL] [Abstract][Full Text] [Related]
44. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
[TBL] [Abstract][Full Text] [Related]
45. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.
Liu C; Yu Y; Yin G; Zhang J; Wen W; Ruan X; Li D; Zhang S; Cai W; Gao M; Chen L
Biochem Biophys Res Commun; 2017 Jan; 482(4):590-596. PubMed ID: 27864143
[TBL] [Abstract][Full Text] [Related]
46. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
47. Genetic aspects of familial thyroid cancer.
Morrison PJ; Atkinson AB
Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
[TBL] [Abstract][Full Text] [Related]
48. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
49. Hereditary and familial thyroid tumours.
Guilmette J; Nosé V
Histopathology; 2018 Jan; 72(1):70-81. PubMed ID: 29239041
[TBL] [Abstract][Full Text] [Related]
50. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
51. Familial Papillary Thyroid Carcinoma (FPTC): a Retrospective Analysis in a Sample of the Bulgarian Population for a 10-Year Period.
Vidinov K; Nikolova D
Endocr Pathol; 2017 Mar; 28(1):54-59. PubMed ID: 27771834
[TBL] [Abstract][Full Text] [Related]
52. Coincidence of primary hyperparathyroidism and nonmedullary thyroid carcinoma.
Lehwald N; Cupisti K; Krausch M; Ahrazoglu M; Raffel A; Knoefel WT
Horm Metab Res; 2013 Sep; 45(9):660-3. PubMed ID: 23757116
[TBL] [Abstract][Full Text] [Related]
53. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
54. [Hereditary thyroid carcinoma and its molecular diagnostics].
Dvořáková S; Václavíková E; Sýkorová V; Hálková T; Bendlová B
Cesk Patol; 2014 Apr; 50(2):81-6. PubMed ID: 24758503
[TBL] [Abstract][Full Text] [Related]
55. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
56. Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing.
Tous C; Muñoz-Redondo C; Bravo-Gil N; Gavilan A; Fernández RM; Antiñolo J; Navarro-González E; Antiñolo G; Borrego S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175550
[TBL] [Abstract][Full Text] [Related]
57. Is familial nonmedullary thyroid carcinoma more aggressive than sporadic nonmedullary thyroid carcinoma?
Malchoff CD; McDonald TJ
Thyroid; 2014 Apr; 24(4):782-3. PubMed ID: 24494807
[No Abstract] [Full Text] [Related]
58. Familial follicular cell tumors: classification and morphological characteristics.
Nosé V
Endocr Pathol; 2010 Dec; 21(4):219-26. PubMed ID: 20878367
[TBL] [Abstract][Full Text] [Related]
59. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Zhang T; Xing M
J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
[TBL] [Abstract][Full Text] [Related]
60. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
